US Lawmakers Scrutinise the Cost of Prescription Medicines

A congressional committee convened this week to examine how drug manufacturers set list prices, the role of pharmacy benefit managers in negotiations, and whether federal programmes such as Medicare are paying fair market rates. The hearing followed months of public pressure from patient advocacy groups, employer coalitions, and bipartisan members who argue that persistent price growth has outpaced inflation and wage gains. Lawmakers questioned executives from several of the country's largest pharmaceutical companies, along with representatives from the generic sector and a major pharmacy benefit manager, signalling a widening inquiry into pricing practices across the supply chain.

For Australian readers, the proceedings offer a useful counterpoint to debates held closer to home. While the Pharmaceutical Benefits Scheme keeps most prescription costs predictable in Australia, ongoing tensions between local suppliers, multinational manufacturers, and the federal government continue to shape which medicines reach pharmacies in Sydney, Melbourne, and regional centres quickly and affordably. The US hearings underscore how pricing transparency, market exclusivity, and rebate structures can produce very different patient outcomes in different jurisdictions.

What the committee wanted to know

The committee chair opened the session by noting that Americans spend more per capita on medicines than citizens of any other wealthy nation, yet health outcomes on several measures lag behind comparable countries. Members asked executives to justify list price increases that exceeded ten per cent year on year for certain insulins, inhalers, and oncology therapies. They also pressed for clarity on how rebates negotiated with insurers ultimately translate into savings at the pharmacy counter, or whether they are absorbed elsewhere in the distribution chain.

Witnesses included chief executives from three major brand-name manufacturers, the head of a generic drug association, and an executive from a pharmacy benefit manager. Lawmakers requested documents on internal pricing models, patent extension strategies, and contracts with group purchasing organisations. The committee indicated that further subpoenas could follow if voluntary disclosure was deemed insufficient.

How drug pricing actually works

Pharmaceutical pricing in the United States is shaped by a complex series of negotiations. Manufacturers set a wholesale acquisition cost, which is rarely the price paid by insurers or patients. Pharmacy benefit managers negotiate rebates and discounts on behalf of health plans, hospitals, and employer-sponsored programmes. The final amount paid by an uninsured consumer can be dramatically higher than the negotiated rate that a large insurer receives for the same product.

In Australia, the system operates differently. The Pharmaceutical Benefits Scheme sets a single government subsidised price for approved medicines, with patients paying a fixed co-payment that is reviewed annually. The PBS keeps most essential therapies affordable in suburban pharmacies in Brisbane and Perth, as well as in rural towns served by the Rural Pharmacy Maintenance Allowance. This structural difference explains why Australian consumers rarely encounter the volatility described in the US hearing, even when the same manufacturer sells the same molecule in both countries.

The patient burden across the Pacific

Patient witnesses told the committee of difficult choices, including rationing insulin, delaying refills, or travelling to clinics in other states to access charity care. Several described seeking medications through Canadian pharmacies, a workaround that highlights the frustration with domestic pricing. The committee also heard from hospital pharmacists who described occasional shortages driven by opaque contracting arrangements, where a product may be technically available yet unaffordable for certain providers.

Australian patient groups expressed cautious interest in the proceedings. Organisations representing people with rare diseases in Adelaide and Hobart have long argued that PBS listings do not always keep pace with new therapies approved overseas, particularly for ultra-rare conditions where individual courses of treatment can exceed several hundred thousand dollars. Advocates continue to lobby for streamlined pathways and expanded compassionate access programmes, while the Therapeutic Goods Administration reviews applications for newer agents.

Industry defends the model

Pharmaceutical executives defended their pricing as necessary to fund research and development, noting that bringing a single new molecule to market can cost more than two billion US dollars and take over a decade. They pointed to significant discounts provided to federal programmes, hospital systems, and low-income patients, and warned that aggressive price controls could chill investment in early-stage research. Executives also argued that gross-to-net rebates have grown steadily, reducing the actual revenue retained per prescription even as list prices climb.

Representatives from the generic sector offered a contrasting view, describing how consolidation among manufacturers has reduced competition and allowed prices for some off-patent medicines to spike unexpectedly. The pharmacy benefit manager witness pushed back against critics, arguing that intermediaries drive down costs for employers and unions but acknowledged that the system lacks transparency for consumers who never see the negotiated rate.

Possible legislative responses

Lawmakers suggested several directions for reform, including caps on out-of-pocket costs for Medicare beneficiaries, mandatory disclosure of rebate totals, and adjustments to patent term restoration that could accelerate generic entry. Some proposals would allow Medicare to negotiate directly on a broader range of products, a concept already embedded in recent legislation covering a limited set of drugs. Others focused on penalising price spikes on long-established medicines that face no meaningful competition.

The Australian experience is again instructive here. When the PBS lists a new medicine, the manufacturer negotiates a price based on clinical benefit, cost-effectiveness analysis, and budget impact, with provisions for price reductions when patents expire. Health economists in Canberra have argued that this disciplined approach delivers better value than open-ended negotiation in fragmented markets, though they concede that access to cutting-edge therapies can lag behind the United States and Europe.

What to watch next

The committee scheduled further hearings for the coming months and indicated that testimony from insurers, hospital purchasing groups, and patient advocates would follow. Analysts expect a legislative package to emerge by the end of the session, though its scope will depend on negotiations across party lines and continued public attention. For consumers, the most immediate signals will come from proposed changes to Medicare negotiation authority, transparency requirements, and any restrictions on so-called evergreening patents that extend exclusivity without meaningful innovation.

Readers can follow NEWINFORMERS for ongoing coverage of pharmaceutical policy, healthcare market trends, and consumer-focused explainers across our health, politics, and lifestyle sections. Subscribe to our weekly newsletter for curated updates, or share this article with colleagues interested in how drug pricing shapes access to care on both sides of the Pacific.